Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $17.00.

A number of equities analysts have weighed in on ZURA shares. Wedbush upped their price objective on shares of Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. William Blair assumed coverage on Zura Bio in a report on Wednesday, July 8th. They issued an “outperform” rating for the company. Guggenheim raised their price objective on Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th.

Zura Bio Price Performance

ZURA opened at $5.85 on Monday. The firm’s 50 day moving average is $5.21 and its 200-day moving average is $5.39. Zura Bio has a 52-week low of $1.88 and a 52-week high of $7.44. The firm has a market capitalization of $555.05 million, a P/E ratio of -5.18 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. Equities analysts expect that Zura Bio will post -0.81 earnings per share for the current fiscal year.

Institutional Trading of Zura Bio

Several institutional investors have recently added to or reduced their stakes in ZURA. Montanova Capital LLC boosted its stake in Zura Bio by 4.1% during the 2nd quarter. Montanova Capital LLC now owns 9,443,001 shares of the company’s stock valued at $55,714,000 after acquiring an additional 376,000 shares during the last quarter. Bank of America Corp DE increased its position in shares of Zura Bio by 3,007.7% in the 1st quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock worth $812,000 after purchasing an additional 132,130 shares during the last quarter. Stempoint Capital LP bought a new stake in shares of Zura Bio in the 1st quarter worth about $4,483,000. ADAR1 Capital Management LLC raised its stake in shares of Zura Bio by 12.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company’s stock valued at $3,751,000 after purchasing an additional 68,338 shares in the last quarter. Finally, EcoR1 Capital LLC bought a new position in shares of Zura Bio during the first quarter worth about $7,019,000. 61.14% of the stock is owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.